The Medicines Company (NASDAQ:MDCO): The mean estimate for the short term price target for The Medicines Company (NASDAQ:MDCO) stands at $49.29 according to 7 Analysts. The higher price target estimate for the stock has been calculated at $65 while the lower price target estimate is at $41.
Many analysts have stated their opinion on the company shares. Cowen & Company initiates coverage on The Medicines Company (NASDAQ:MDCO) The current rating of the shares is Outperform. The rating by the firm was issued on May 5, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, Cox Christopher T, officer (EVP & Chief Corp. Dev. Officer) of Medicines Co /De, executed a transaction worth $1,729,956 on June 8, 2016. A total of 45,985 shares were purchased at an average price of $37.62. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
The Medicines Company (NASDAQ:MDCO) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.69 points or 1.85% at $36.57 with 1,013,257 shares getting traded. Post opening the session at $36.76, the shares hit an intraday low of $36.26 and an intraday high of $37.46 and the price was in this range throughout the day. The company has a market cap of $2,563 million and the number of outstanding shares have been calculated to be 70,072,431 shares. The 52-week high of The Medicines Company (NASDAQ:MDCO) is $43.79 and the 52-week low is $25.38.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.